Immunoglobulin supplementation and longer dosing intervals reduce risk of infections in patients with RRMM treated with teclistamab. - Smits F; Groen K; Korst CLBM; Frerichs KA; Kuipers I; Kruyswijk S; de Ruijter MEM; Nasserinejad K; Zweegman S; van de Donk NWCJ (Blood cancer journal, 2026)